Hijnen Marcel, He Qiushui, Schepp Rutger, Van Gageldonk Pieter, Mertsola Jussi, Mooi Frits R, Berbers Guy A M
Laboratory for Vaccine Preventable Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
Scand J Infect Dis. 2008;40(2):94-104. doi: 10.1080/00365540701642138.
Although vaccines against Bordetella pertussis, the causative agent of whooping cough, have been in use for over 50 y, the disease has remained endemic and is still a public health problem in many countries. It has been shown that antibody titres against pertactin, which is 1 of the exposed virulence factors of pertussis, correlate with protection and pertactin is now 1 of the components of most acellular pertussis vaccines. However, little is known about the structure and location of protective epitopes on pertactin. Here we set out to investigate the antibody response using naturally occurring pertactin variants and deletion derivates. We found the N-terminus of pertactin to be immunodominant in both rabbits and humans. In contrast to vaccinated rabbits, we could not detect pertactin type-specific antibodies in human sera. In conclusion, these results show for the first time to which defined regions of the pertactin molecule antibody responses are induced. It also suggests that the amount of pertactin type-specific antibodies will not be very large and that the variation in pertactin probably will not constitute a problem in highly immune individuals.
尽管针对百日咳博德特氏菌(百日咳的病原体)的疫苗已经使用了50多年,但该疾病仍然流行,在许多国家仍是一个公共卫生问题。已经表明,针对百日咳黏附素(百日咳暴露的毒力因子之一)的抗体滴度与保护作用相关,并且百日咳黏附素现在是大多数无细胞百日咳疫苗的成分之一。然而,关于百日咳黏附素上保护性表位的结构和位置知之甚少。在这里,我们着手使用天然存在的百日咳黏附素变体和缺失衍生物来研究抗体反应。我们发现百日咳黏附素的N末端在兔子和人类中都是免疫显性的。与接种疫苗的兔子不同,我们在人类血清中检测不到百日咳黏附素类型特异性抗体。总之,这些结果首次表明百日咳黏附素分子的哪些特定区域会诱导抗体反应。这也表明百日咳黏附素类型特异性抗体的数量不会很多,并且百日咳黏附素的变异在高度免疫的个体中可能不会构成问题。